Nomura Asset Management Co. Ltd. Has $84.45 Million Stock Position in Kenvue Inc. (NYSE:KVUE)

Nomura Asset Management Co. Ltd. cut its position in Kenvue Inc. (NYSE:KVUE) by 9.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,955,483 shares of the company’s stock after selling 389,243 shares during the period. Nomura Asset Management Co. Ltd. owned 0.21% of Kenvue worth $84,450,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in KVUE. Providence Capital Advisors LLC bought a new stake in shares of Kenvue during the fourth quarter valued at approximately $2,557,000. Norges Bank bought a new stake in Kenvue during the 4th quarter valued at $521,348,000. Blair William & Co. IL raised its holdings in Kenvue by 0.9% during the fourth quarter. Blair William & Co. IL now owns 194,250 shares of the company’s stock worth $4,147,000 after buying an additional 1,755 shares during the last quarter. Caisse Des Depots ET Consignations acquired a new position in Kenvue during the fourth quarter worth $4,978,000. Finally, NEOS Investment Management LLC grew its holdings in shares of Kenvue by 31.5% during the fourth quarter. NEOS Investment Management LLC now owns 103,849 shares of the company’s stock valued at $2,217,000 after buying an additional 24,888 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $23.52 on Friday. The firm has a market capitalization of $44.95 billion, a PE ratio of 44.38, a P/E/G ratio of 2.62 and a beta of 1.25. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The company has a 50-day moving average price of $22.27 and a two-hundred day moving average price of $22.46. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.49%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and cut their target price for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. Piper Sandler boosted their price objective on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Canaccord Genuity Group raised their target price on Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Finally, Evercore ISI began coverage on Kenvue in a research note on Monday. They set an “in-line” rating and a $25.00 target price on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Kenvue has an average rating of “Hold” and an average price target of $24.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.